Results 1 to 10 of about 177,234 (149)
Immune checkpoint inhibitors in melanoma [PDF]
Lancet, The, 2021 Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and anti-PD-1 antibodies, have revolutionised the management of many cancers, particularly advanced melanoma, for which tumour regression and long-term durable cancer control ...
Matteo S Carlino +2 more
exaly +3 more sources
Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients
Kidney International Reports, 2020 Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients.
Sandhya Manohar +4 more
doaj +3 more sources
Negative Immune Checkpoint Inhibitors
PharmaceuticsCheckpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate ...
Magda Drewniak-Świtalska +2 more
doaj +3 more sources
Immune Checkpoint Inhibitors in Cancer Therapy
Current Oncology, 2022 The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and
Yavar Shiravand +2 more
exaly +7 more sources
Immune checkpoint inhibitors [PDF]
Journal of Experimental Medicine, 2021 Three papers by James Allison and Tasuku Honjo published in JEM between 1995 and 2000 crystallized seminal insights into the role of CTLA-4 and PD-1 in immunosuppression (Krummel and Allison. 1995. J. Exp. Med.https://doi.org/10.1084/jem.182.2.459; van Elsas et al. 1999. J. Exp. Med.https://doi.org/10.1084/jem.190.3.355; Freeman et al. 2000. J.
Kroemer, Guido, Zitvogel, Laurence
+6 more sources
Immune checkpoint inhibitors [PDF]
Journal of Cell Biology, 2019 Hui details the cell biology underlying the action of immune checkpoint inhibitors.
Pawel Kalinski, Per Basse
+10 more sources
Perioperative immune-checkpoint inhibitors for muscle-invasive bladder cancer [PDF]
Drugs in ContextMuscle-invasive bladder cancer (MIBC) has a high risk of recurrence following radical cystectomy. Neoadjuvant cisplatin-based chemotherapy has been used for decades to lower recurrence rates but a significant proportion of patients still have disease ...
Albert Jang +6 more
doaj +2 more sources
Immune Checkpoint Inhibitors and the Heart [PDF]
Frontiers in Cardiovascular Medicine, 2021 Immune checkpoint inhibitors (ICIs) represent a break-through treatment for a large number of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for primary tumours and for metastases, adjuvant/neo-adjuvant therapy.
Diana Larisa Mocan-Hognogi +11 more
openaire +3 more sources
Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review [PDF]
Intestinal Research, 2023 Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system.
Sung Wook Hwang +2 more
doaj +1 more source
Cardiotoxicity of Immune Checkpoint Inhibitors [PDF]
Current Oncology Reports, 2021 Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be associated with high rates of morbidity and mortality.
Rushin P. Patel +6 more
openaire +2 more sources